Emetinol refers to Emetinofovir and Propofol Tenofovir refers to Tenofovir Tenofovir Tenofovir Propionate Fumarate, the difference between the two is in the dosage of the drug, adverse effects, drug resistance and so on. 1. Emtinofovir: this drug belongs to the nucleoside reverse transcriptase inhibitors, used in the treatment of chronic hepatitis B in adults, overcoming the potential nephrotoxic effects of tenofovir disoproxil fumarate as well as the effects of bone metabolism, the safety of which is more guaranteed. Common adverse effects include elevated blood parathyroid hormone and decreased bone density. Studies have shown that the chances of emergence of resistance to Emetinofovir are low. As the precursor substance of Tenofovir, Emitinofovir is optimized in structure, which makes it easier for the drug to pass through the liver cell membrane, and the drug is metabolized into the active product Tenofovir Diphosphate in the liver cells, thus it has better targeting effect, and the dosage is only 1/10 of Tenofovir Fumarate, which can exert the same antiviral activity as Tenofovir. 2. Tenofovir disoproxil fumarate: This drug is an anti-hepatitis B virus drug, which can be used for the treatment of chronic hepatitis B in adults and adolescent children (aged 12 years and above, weighing at least 35 kg). Common adverse reactions include nausea, diarrhea, fatigue, increased alanine aminotransferase, and joint pain. Resistance is slightly more likely to occur than with Emtinofovir. In conclusion, patients must use the above medications under the supervision of a physician and should never self-medicate to avoid adverse effects.